Version 1
: Received: 23 August 2021 / Approved: 25 August 2021 / Online: 25 August 2021 (11:03:27 CEST)
How to cite:
Lin, J. Critical Analysis of Corneal Cross-Linking (Part-II): Resolving the Controversial Issues (Theory Versus Measurements). Preprints2021, 2021080488. https://doi.org/10.20944/preprints202108.0488.v1
Lin, J. Critical Analysis of Corneal Cross-Linking (Part-II): Resolving the Controversial Issues (Theory Versus Measurements) . Preprints 2021, 2021080488. https://doi.org/10.20944/preprints202108.0488.v1
Lin, J. Critical Analysis of Corneal Cross-Linking (Part-II): Resolving the Controversial Issues (Theory Versus Measurements). Preprints2021, 2021080488. https://doi.org/10.20944/preprints202108.0488.v1
APA Style
Lin, J. (2021). Critical Analysis of Corneal Cross-Linking (Part-II): Resolving the Controversial Issues (Theory Versus Measurements)<strong> </strong>. Preprints. https://doi.org/10.20944/preprints202108.0488.v1
Chicago/Turabian Style
Lin, J. 2021 "Critical Analysis of Corneal Cross-Linking (Part-II): Resolving the Controversial Issues (Theory Versus Measurements)<strong> </strong>" Preprints. https://doi.org/10.20944/preprints202108.0488.v1
Abstract
To resolve the controversial issues of UV-light-initiatedcornealcollagen cross-linking (CXL) by theoretical formulas and measured clinical outcomes.The controversial issues are addressed and resolved by analytical formulas including: the validation of Bunsen Roscoe law (BRL), the cutoff light intensity, the minimum corneal thickness, the demarcation line depth, the role of oxygen riboflavin (RF) concentration. The overall CXL efficacy is governed by UV-A light intensity, dose, exposure time, mode of exposure (pulsed or CW), riboflavin concentration, diffusion and drops pre-operation and interoperation administration, concentration of oxygen in the stromal tissue (pre-op and inter-op), and environmental conditions. The length of the riboflavin presoaking time and viscosity of the riboflavin film also affect the crosslink depth. Analytic formulas are derived for the scaling laws for type-I and type-II efficacy, given by the square-root of light intensity, and light dose, respectively. The controversial issues of CXL may be partially resolved via analytic formulas, and compared with measurements. The scaling laws of type-I and type-II efficacy are different and given by analytic formulas. Our formulas also predict the maximum light intensity and the minimum corneal thickness, which are consistent with measurements.
Medicine and Pharmacology, Medicine and Pharmacology
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
